{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:55:46Z","timestamp":1791932146459,"version":"4.3.4"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:p>This systematic review aims to assess the efficacy and safety of various intravenous methylprednisolone (IVMP) protocols for treating active moderate to severe thyroid eye disease (TED) and to find the most effective regimen with the least side effects. We conducted a comprehensive literature search adhering to PRISMA guidelines across PubMed, Medline, Embase, Web of Science, and Scopus databases from March 2008 to March 2024 to find relevant studies. Included studies were randomized controlled trials (RCTs), nonrandomized trials, cohort studies, case\u2013control studies, case series, and case reports in English, investigating IVMP usage in adults with active moderate to severe TED. Outcomes focused on disease activity, exophthalmos improvement, diplopia resolution, recurrence, need of additional treatment, and associated adverse events. Of the 274 screened articles, 15 were included, involving 1065 participants. There were six RCTs (two multicentric), six retrospective studies, and three prospective case series from March 2008 to March 2024. Regimens were categorized into low dose (LD) \u2264 2.5 g, medium dose (MD) &gt;2.5 g to 4.5 g, and high dose (HD) &gt;4.5 g, with intervals of daily, weekly (most common), and monthly, over 4 to 26 weeks, typically 12 weeks. The MD (4.5 g) regimen was the most common followed, and it significantly improved Clinical Activity Score and quality of life with low side effects. The main limitations of this study are the heterogeneity of included studies, duration of follow-up, and IVMP regimens, which may affect the comparability and generalizability of the results. The weekly IVMP (4.5 g) regimen optimally treats moderate to severe TED. However, future research should focus on large-scale trials to determine the optimal IVMP regimen while addressing variability in managing recurrence, additional treatments, and the timing of rehabilitative surgeries.<\/jats:p>","DOI":"10.4103\/ijo.ijo_1808_24","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T15:00:21Z","timestamp":1753714821000},"page":"1100-1107","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of various Intravenous Methylprednisolone regimens in Moderate to Severe Thyroid Eye Disease: A systematic review"],"prefix":"10.4103","volume":"73","author":[{"given":"Ankita","family":"Aishwarya","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGI), Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divanshi","family":"Shrivastava","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGI), Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adarsh Kumar","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Centre of Biomedical Research, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGI), Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachna","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGI), Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"R1-20260421","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1089\/105072502761016476","article-title":"Epidemiology and prevention of Graves\u2019 ophthalmopathy","volume":"12","author":"Wiersinga","year":"2002","journal-title":"Thyroid"},{"key":"R2-20260421","first-page":"477","article-title":"The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota","volume":"92","author":"Bartley","year":"1994","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R3-20260421","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s13643-020-01459-7","article-title":"Prevalence of hyperthyroidism, hypothyroidism, and euthyroidism in thyroid eye disease: A systematic review of the literature","volume":"9","author":"Mu\u00f1oz-Ortiz","year":"2020","journal-title":"Syst Rev"},{"key":"R5-20260421","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.sjopt.2010.10.001","article-title":"Medical management of thyroid eye disease","volume":"25","author":"Yang","year":"2011","journal-title":"Saudi J Ophthalmol"},{"key":"R6-20260421","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1080\/01676830.2018.1553189","article-title":"Efficacy and safety of pulsed intravenous methylprednisolone in early active thyroid eye disease","volume":"38","author":"Young","year":"2019","journal-title":"Orbit"},{"key":"R7-20260421","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1530\/EJE-07-0666","article-title":"Consensus statement of the European Group on Graves\u2019 orbitopathy (EUGOGO) on management of GO","volume":"158","author":"Bartalena","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"R8-20260421","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"R9-20260421","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1507\/endocrj.EJ16-0083","article-title":"Comparison of two different regimens of intravenous methylprednisolone for patients with moderate to severe and active Graves\u2019 ophthalmopathy: A prospective, randomized controlled trial","volume":"64","author":"He","year":"2017","journal-title":"Endocr J"},{"key":"R10-20260421","doi-asserted-by":"crossref","first-page":"e13608","DOI":"10.1111\/ijcp.13608","article-title":"Comparison of efficacy and safety of parenteral versus parenteral and oral glucocorticoid therapy in Graves\u2019 orbitopathy","volume":"74","author":"Nedeljkovic Beleslin","year":"2020","journal-title":"Int J Clin Pract"},{"key":"R11-20260421","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u2019 orbitopathy","volume":"97","author":"Bartalena","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R12-20260421","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","article-title":"Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): A randomised, observer-masked, multicentre trial","volume":"6","author":"Kahaly","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R13-20260421","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1530\/EJE-07-0558","article-title":"Methylprednisolone pulse therapy for patients with moderately severe Graves\u2019 orbitopathy: A prospective, randomized, placebo-controlled study","volume":"158","author":"van Geest","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"R14-20260421","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1575-0922(09)70841-1","article-title":"Treatment of Graves\u2019 ophthalmopathy with high-dose intravenous methylprednisolone: A comparison of two dosing regimens","volume":"56","author":"S\u00e1nchez-Ortiga","year":"2009","journal-title":"Endocrinol Nutr"},{"key":"R15-20260421","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3109\/01676831003660663","article-title":"The role of intravenous methylprednisolone immunosuppression in the management of active thyroid eye disease","volume":"29","author":"Tambe","year":"2010","journal-title":"Orbit"},{"key":"R16-20260421","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1210\/jc.2013-3919","article-title":"A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves\u2019 ophthalmopathy","volume":"99","author":"Zhu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"R17-20260421","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/IOP.0000000000000036","article-title":"What is the aim of immunosuppressive treatment in patients with graves\u2019 orbitopathy?","volume":"30","author":"Yang","year":"2014","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"R18-20260421","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1136\/bjophthalmol-2014-306463","article-title":"Smoking was associated with poor response to intravenous steroids therapy in Graves\u2019 ophthalmopathy","volume":"99","author":"Xing","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"R19-20260421","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3892\/etm.2016.3446","article-title":"Short and long-term effects of high-dose intravenous methylprednisolone pulse therapy on thyroid-associated ophthalmopathy","volume":"12","author":"Liu","year":"2016","journal-title":"Exp Ther Med"},{"key":"R20-20260421","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3892\/etm.2020.9282","article-title":"Comparison of two regimens for patients with thyroid-associated ophthalmopathy receiving intravenous methyl prednisolone: A single center prospective randomized trial","volume":"20","author":"Mu","year":"2020","journal-title":"Exp Ther Med"},{"key":"R21-20260421","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s40618-019-01174-8","article-title":"Tear inflammatory cytokines and ocular surface changes in patients with active thyroid eye disease treated with high-dose intravenous glucocorticoids","volume":"43","author":"Xu","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"R22-20260421","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40618-020-01322-5","article-title":"Changes in ocular biomechanics after treatment for active Graves\u2019 orbitopathy","volume":"44","author":"Li","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"R23-20260421","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.3390\/jcm12093244","article-title":"Efficacy and safety of 6-weekly versus 12-weekly intravenous methylprednisolone in moderate-to-severe active thyroid-associated ophthalmopathy","volume":"12","author":"Lai","year":"2023","journal-title":"J Clinl Med"},{"key":"R24-20260421","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1001\/jamaophthalmol.2021.6284","article-title":"Proptosis and diplopia response with teprotumumab and placebo vs the recommended treatment regimen with intravenous methylprednisolone in moderate to severe thyroid eye disease: A meta-analysis and matching-adjusted indirect comparison","volume":"140","author":"Douglas","year":"2022","journal-title":"JAMA Ophthalmology"},{"key":"R25-20260421","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41433-024-02967-9","article-title":"The changing landscape of thyroid eye disease: Current clinical advances and future outlook","volume":"38","author":"Moledina","year":"2024","journal-title":"Eye"},{"key":"R26-20260421","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ajo.2006.02.047","article-title":"Pathogenesis of graves ophthalmopathy: Implications for prediction, prevention, and treatment","volume":"142","author":"Garrity","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R27-20260421","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.amjmed.2011.03.001","article-title":"Graves\u2019 disease: Diagnostic and therapeutic challenges (multimedia activity)","volume":"124","author":"Kahaly","year":"2011","journal-title":"Am J Med"},{"key":"R28-20260421","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/bjo.82.7.773","article-title":"Development of a disease specific quality of life questionnaire for patients with Graves\u2019 ophthalmopathy: The GO-QOL","volume":"82","author":"Terwee","year":"1998","journal-title":"Br J Ophthalmol"},{"key":"R29-20260421","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/archopht.123.4.491","article-title":"Psychological disturbance in graves ophthalmopathy","volume":"123","author":"Farid","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"R30-20260421","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1530\/eje.0.1510549","article-title":"Impaired health-related quality of life in Graves\u2019 disease. A prospective study","volume":"151","author":"Elberling","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"R31-20260421","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1089\/105072502753600205","article-title":"Psychosocial factors in subjects with thyroid-associated ophthalmopathy","volume":"12","author":"Kahaly","year":"2002","journal-title":"Thyroid"},{"key":"R32-20260421","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.autrev.2017.12.012","article-title":"Quality of life and neuropsychiatric disorders in patients with Graves\u2019 Orbitopathy: Current concepts","volume":"17","author":"Bruscolini","year":"2018","journal-title":"Autoimmun Rev"},{"key":"R33-20260421","first-page":"164","article-title":"Quality of life in patients with thyroid eye disease","volume":"4","author":"Bahmani-Kashkouli","year":"2009","journal-title":"J Ophthalmic Vis Res"},{"key":"R34-20260421","first-page":"343","article-title":"Thyroid eye disease","volume":"119","author":"Szelog","year":"2022","journal-title":"Mo Med"},{"issue":"Suppl 1","key":"R35-20260421","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1210\/clinem\/dgac328","article-title":"Understanding pathogenesis intersects with effective treatment for thyroid eye disease","volume":"107","author":"Smith","year":"2022","journal-title":"J Clinl Endocrinol Metab"},{"key":"R36-20260421","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/WNO.0000000000000132","article-title":"The pathophysiology of thyroid eye disease","volume":"34","author":"Shan","year":"2014","journal-title":"J Neuroophthalmol"},{"key":"R37-20260421","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1167\/iovs.14-14002","article-title":"Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy","volume":"55","author":"Wang","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R38-20260421","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/eje.0.1480491","article-title":"Multi-center study on the characteristics and treatment strategies of patients with Graves\u2019 orbitopathy: The first European Group on Graves\u2019 Orbitopathy experience","volume":"148","author":"Prummel","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"R40-20260421","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1530\/EJE-09-0383","article-title":"The patient experience of services for thyroid eye disease in the United Kingdom: Results of a nationwide survey","volume":"161","author":"Estcourt","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"R41-20260421","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/archophthalmol.2011.29","article-title":"Rundle and his curve","volume":"129","author":"Bartley","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"R42-20260421","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1210\/jc.2010-1962","article-title":"Intravenous glucocorticoids for Graves\u2019 orbitopathy: Efficacy and morbidity","volume":"96","author":"Zang","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R43-20260421","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1210\/jc.2005-0148","article-title":"Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves\u2019 orbitopathy","volume":"90","author":"Kahaly","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R44-20260421","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1742-1241.2006.01004.x","article-title":"Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves\u2019 ophthalmopathy: IVGC vs. OGC in Graves\u2019 ophthalmopathy","volume":"61","author":"Aktaran","year":"2006","journal-title":"Int J Clin Pract"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_1808_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:27:31Z","timestamp":1787837251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_1808_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_1808_24","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"2024-07-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}